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13,396 males representing 212.7 million American adults aged
18 to 85+ years. Nonparametric regression models were
employed to express migraine prevalence as a function of age
separately for each sex group. The salient characteristics of the
ﬁtted functions were evaluated by examining the ﬁrst and second
derivatives, corresponding to the velocity and the acceleration of
prevalence over the age continuum. RESULTS: Study results
suggest that migraine prevalence increases with age until about
34 years, where it reaches a maximum, then starts declining until
75 years where it reaches a plateau for both sexes. For females,
the greatest rate of decline in migraine prevalence starts at 41
years and continues until age 63 where it reaches its minimum.
The rate of decline in migraine prevalence for males, on the other
hand, seems to be decreasing in a smooth monotonic fashion
starting age 34 and reaches the female rate of change at 78 years.
The dramatic change in both the slope and the curvature of the
function for females around the perimenopausal age range war-
rants attention. CONCLUSIONS: These ﬁndings provide indi-
rect evidence for the phenomenon of menstrual migraine. The
inﬂection points on the female curve correspond to the age range
of perimenopause and menopause in U.S. women. These inﬂec-
tion points are not observed on the male curve.
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OBJECTIVES: Phase III clinical trials showed novel drugs intro-
duced in the 1990s modiﬁed the natural history (NH) of relaps-
ing-remitting onset deﬁnite multiple sclerosis (MS). A Nova
Scotia Phase IV “real world” observational study conﬁrmed the
short-term effectiveness of these disease modifying therapies
(MS-DMT), measured by Extended Disability Status Scale
(EDSS) increase avoided per patient per year. This analysis pro-
jects these short-term results over a 20-year horizon to estimate
long-term health outcomes of MS-DMT. METHODS: A proba-
bilistic Markov model estimated EDSS progression for NH and
MS-DMT cohorts with relapsing-remitting onset MS over a 20-
year horizon. The model was based on 591 patients receiving
MS-DMT from the Dalhousie MS Research Unit, stratiﬁed into
three subgroups by ﬁnal classiﬁcation and disability severity: 1)
mild relapsing-remitting MS (RRMS), 2) mild secondary-pro-
gressive MS (SPMS) and 3) mild or moderate SPMS. Health out-
comes were measured as EDSS disability adjusted life years
(DALYs) avoided per patient compared to NH. Relative beneﬁt
was deﬁned as DALY burden avoided relative to expected
DALYs given NH. The baseline analysis was a “best-case” sce-
nario with full compliance for 20 years. RESULTS: The model
found statistically signiﬁcant beneﬁt in all three subgroups.
Among the mild severity subgroups, there were 1.7 (95%
CI:1.2–2.2) DALYs avoided among RRMS patients and 2.6
(1.5–3.6) DALYs avoided among SPMS patients, for a combined
beneﬁt of 1.9 (1.2–3.2) DALYs avoided, or a 42% (20%–91%)
relative beneﬁt. Among the mild or moderate SPMS patients
there were 1.1 (0.3–1.9) DALYs avoided (14%; 3–30%).
Overall, the combined cohort had a beneﬁt of 1.5 (0.5–2.1)
DALYs avoided (29%; 6–63%). CONCLUSIONS: MS-DMT
can have signiﬁcant long-term beneﬁt in terms of DALYs
avoided, particularly in mild subgroups. This analysis is the ﬁrst
to model long-term change in mean EDSS, rather than delayed
time to speciﬁc EDSS endpoints, and may help guide MS-DMT
coverage decisions.
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A LITERATURE REVIEW OF PATIENT-REPORTED OUTOMES
(PROS), NEUROPSYCHOLOGICAL AND COGNITIVE
INSTRUMENTS IN PARKINSON’S DISEASE
Staniek V, Emery MP
Mapi Research Trust, Lyon, France
OBJECTIVES: To describe and compare the domains and psy-
chometric properties of selected Patient Reported Outcomes
(PROs) instruments, neuropsychological and cognitive, devel-
oped and/or used in patients with Parkinson’s disease (PD).
METHODS: A systematic literature review of published studies
was conducted using MEDLINE (1990–2006), EMBASE
(1990–2006) and the Mapi Research Trust databases. Only
studies describing the development or use of a referenced instru-
ment assessing Health-Related Quality Of Life (HRQL), Activi-
ties of Daily Living (ADL), Fatigue/sleep, Neuropsychological
and cognitive measures were included in the review. Instruments
were selected if they were speciﬁcally developed for Parkinson’s
disease, or used in clinical trials and for which psychometric
properties were available. Caregiver reports were not included.
RESULTS: Sixty instruments were identiﬁed and 35 were
selected for in-depth review. Seven questionnaires measured
HRQL (2 generic and 5 PD speciﬁc). Of these, the PDQUALIF
and the PDQ-39 are well validated but are not always sensitive
to changes in RCTs. Four instruments assessed ADL/disability,
with the UPDRS being generally used as a primary endpoint in
RCTs. Six instruments measured sleep or fatigue, most of them
have been validated in PD patients and are sensitive to change.
Two symptoms (motor & non-motor) scales were selected, but
lack evidence of good psychometric properties. Four psycholog-
ical instruments and 12 neuropsychological/cognitive instru-
ments were also selected. Most of these were not validated in PD
patients and failed to demonstrate their sensitivity to change in
clinical trials. CONCLUSIONS: The selected PRO instruments
are very heterogeneous in their levels of validation, psychomet-
ric properties and sensitivity to change in clinical trials, depend-
ing on the dimension measured. For HRQOL, ADL/Disability
and Sleep, reliable measures are available whereas advances 
are still needed to assess symptoms, psychological well-being or
cognition.
PND13
PSICOMETRIC PROPERTIES OF THE TREATMENT
SATISFACTION WITH MEDICINES QUESTIONNAIRE
(SATMED-Q) IN PATIENTS WITH REFRACTORY EPILEPSY
Ruíz MA1, Rejas J2, Palacios G2, Pardo A1, Soto J2
1Universidad Autónoma de Madrid, Madrid, Spain, 2Pﬁzer Spain,
Madrid, Spain
OBJECTIVES: Treatment of epilepsy is still challenging to the
scientiﬁc community. Usually, these patients require more than
one drug. Hence satisfaction with antiepileptic drugs becomes a
major goal, as it is of crucial relevance for seizures control and
patient wellbeing, particularly at the level of anxiety, depression
and quality of life. This study assessed the psychometric prop-
erties of a recently developed questionnaire of Treatment Satis-
faction (SATMED-Q) in subjects with refractory epilepsy.
METHODS: patients with refractory epilepsy from epilepsy and
neurology outpatient clinics, representative of the national dis-
tribution in Spain were included. Sociodemographic, anthropo-
metric data, and the SATMED-Q (Treatment Satisfaction), and
HAD (Anxiety and Depression) questionnaires were collected.
Reliability and validity were determined. Factor analysis was
used to check the instrument original structure. RESULTS: A
sample of 768 consecutive patients [average age of 40.5 (13.5)
years, 50.8% males and 24.3 (13.4) years of disease evolution]
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were enrolled. Only 4.5% were not assessable and 659 (86.5%)
were able to answer the SATMED-Q. The oretical 6 factor solu-
tion explained 82.8% of the available variance; it was well
deﬁned, and all communalities were above 0.76. A strong cor-
relation between Effectiveness and Impact on Daily Activities 
(r = 0.525) was found. Dimensional Cronbach’s á ranged
between 0.857 and 0.936. The one-dimensional ICC was 0.893
(0.890–0.905, 95% CI) and Guttman two-half index was 0.935.
No signiﬁcant correlation was found between age and Treatment
Satisfaction (r = 0.055), Anxiety (r = −0.17), and Depression 
(r = 0.075). Neither between educational level and Anxiety (r =
−0.038), but educational level showed to be related with Depres-
sion (r = −0.204; p < 0.001) and Treatment Satisfaction (r =
0.169; p < 0.001). Treatment Satisfaction dimension levels inter-
act signiﬁcantly with Depression (p < 0.001) and Anxiety (p <
0.011) severity levels. CONCLUSIONS: The psychometric prop-
erties of the SATMED-Q are good in this speciﬁc population.
Signiﬁcant differences in Treatment Satisfaction are found
depending on the Anxiety and Depression level.
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OBJECTIVES: Multiple Sclerosis (MS) is a chronic neurological
disease affecting the central nervous system with a prevalence
rate of 240 per 100,000 in Canada. The prevalence of pain in
MS ranges from 10%–80% (70% in a study we previously per-
formed). Sativex® (SAT) is a new cannabis-based drug approved
in Canada for neuropathic pain in patients with MS. Willing-
ness-to-pay (WTP) elicits the extent of subjects’ preference for
their chosen treatment, expressed as the amount they would
hypothetically be willing to pay in insurance premiums in order
to have access to the treatment. METHODS: The WTP instru-
ment had a decision board (DB) and a questionnaire. A DB is a
visual aid to help clinicians present clinical information about
treatment options in a standardized manner. Two treatment
options were presented on the board used in this study, with text
and data describing them obtained from clinical experts and the
literature. The ﬁrst option was a “cocktail” of three medications:
gabapentin, amytriptylin, and acetaminophen (“pills”), while the
comparator was the same “cocktail” but adding SAT (“pills and
oral spray”). The WTP instrument was administered to 500 par-
ticipants from the general Canadian population, using the
bidding game approach. Descriptive statistics were calculated.
RESULTS: The mean age of the study population was 39 ± 13
years, 56% were female. The DB was facilitated in English
(85%) and French (15%). Of the 500 interviews conducted, 253
respondents chose the “pills and oral spray” option. For these
subjects, the mean WTP per month in additional insurance
premium was CAD $8 (range = $0–$200, median = $4). CON-
CLUSION: Assuming only 51% in a general population are
willing to pay additional premiums as reported, the obtained
WTP would be able to fund the drug for all MS patients with
pain (assumed 70%), with a remaining surplus of $3.24/person.
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OBJECTIVES: This study used a stated preference discrete
choice experiment (DCE) to explore the preferences and will-
ingness to pay (WTP) of RR-MS patients in the UK regarding
the beneﬁts of treatments. METHODS: The attributes in the
DCE included the number of future relapses, presence of new
nerve damage, progression in disability level and out of pocket
cost (to estimate WTP for changes in attribute levels). Partici-
pants were asked to indicate their preference for hypothetical
treatment proﬁles that varied attribute levels based on an orthog-
onal fold-over design. The patient sample (n = 194) was recruited
through advertisement with a patient advocacy group. WTP was
estimated using logit analysis. RESULTS: Eighty-three percent of
patients (mean age 44 years, 82% female) had experienced 1 or
more relapses in the last 2 years and 46% required aid with
ambulation. Patients had a mean annual household income of
≤33,000 and monthly MS-related expenditures of approximately
≤50. The estimated monthly WTP for a combined beneﬁt of 
no disability progression, new nerve damage or relapses was
approximately 9 times their current expenditures and 16% of
their mean annual income. The most highly valued treatment
outcome was avoidance of disability progression in the next year.
Segmented analyses indicated that patients not currently experi-
encing a relapse and those with lower self-reported levels of dis-
ability had higher WTP for improvements in the other treatment
beneﬁt attributes. CONCLUSION: RR-MS patients indicated a
differential demand for avoidance of MS related disability pro-
gression, relapses and nerve damage. Patients who were less
severely affected by their RR-MS were willing to pay more to
reduce the burden of their disease. This study underlines the high
value patients place on the avoidance of MS sequelae, particu-
larly disability progression.
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OBJECTIVES: Aim of our study is to analyse the 30 days mor-
tality of patients over 60 with femoral neck fracture according
to comorbidities at admission. METHODS: Data derives from
the database of National Health Insurance Fund Administration
and based on the S7200 code (femoral neck fracture) of Inter-
national Classiﬁcation of Diseases (ICD) tenth revision and the
codes of comorbidities. The retrospective study is based on
patients discharged in 2000 from the institutions providing deﬁn-
itive care after the primary treatment of femoral neck fracture.
Financial data has been controlled with a nationwide institu-
tional questionnaire. We calculated 30 days mortality as a time
between hospital admission and death. Early mortality rates are
presented according to the dominant occurrence most frequently
found comorbidities. RESULTS: Altogether 3783 patients over
60 years met the inclusion criteria. The overall 30 days mortal-
ity was 9%. The mortality of patients with comorbidities was
9.65%, while without comorbidities it was 2.1%. The early mor-
